bendamustine
Bendamustine is a drug used to treat Chronic Lymphocytic Leukemia, Lymphoma, Mantle Cell Lymphoma, and other conditions. Bendamustine is being actively studied in 62 studies and prior, has been studied in 80.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Hoffmann-La Roche | Samsung Medical Center | Jonathon Cohen |
| M.D. Anderson Cancer Center | Centre Henri Becquerel | Adam Olszewski |
| German CLL Study Group | Columbia University Medical Center | Antonio Pinto |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +6 more
- Saint Louis, MissouriWashington University School of Medicine
2021-05-21
May 21, 2021U
Completed
- Multiple Myeloma
- Melphalan
- Bendamustine
- Berne, SwitzerlandDepartment for Medical Oncology University Hospital/Inselspital
2021-07-29
Jul 29, 2021N
Recruiting
- Hairy Cell Leukemia
- Pentostatin
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022U
Recruiting
- Mantle Cell Lymphoma
- +2 more
- Bendamustine
- Obinutuzumab
- Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022Y
W
Recruiting
- Relapsed T-Cell Lymphoma
- +2 more
- CPI 613
- Bendamustine
- Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
2021-08-27
Aug 27, 2021M
Recruiting
- Lymphoma
- rituximab
- +3 more
- New York, New YorkMemorial Sloan Kettering Cancer Center
2022-03-07
Mar 7, 2022I
Not yet recruiting
- Mantle Cell Lymphoma
- parsaclisib
- +3 more
- (no location specified)
2022-02-14
Feb 14, 2022W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
- Saint Louis, MissouriWashington University School of Medicine
2022-02-02
Feb 2, 2022S
Not yet recruiting
- Relapsed, Refractory, Multiple Myeloma
- Pomalidomide
- +2 more
- Guangzhou, Please Select, ChinaSun Yat-sen University Cancer Center
2021-02-17
Feb 17, 2021S
Withdrawn
- Indolent Non-Hodgkin's Lymphoma
- +3 more
- Duvelisib
- +3 more
- Plainville, Connecticut
- +6 more
2021-03-15
Mar 15, 2021P
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
- Obinutuzumab
- Bendamustine
- München, Bavaria, GermanyKlinikum der Universität München
2021-07-23
Jul 23, 2021U
Active, not recruiting
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
- Madison, WisconsinUniversity of Wisconsin
2021-10-07
Oct 7, 2021H
Completed
- Diffuse, Large B-Cell, Lymphoma
- Polatuzumab Vedotin
- +3 more
- Beijing, China
- +9 more
2022-02-09
Feb 9, 2022A
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- Bendamustine
- Alemtuzumab
- Innsbruck, Tirol, Austria
- +6 more
2022-02-15
Feb 15, 2022U
Terminated
- Lymphoid Leukemia
- +3 more
- Copanlisib
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021U
Completed
- Lymphoma, Non-Hodgkin
- Lymphoma
- Carfilzomib
- +2 more
- Davis, California
- +2 more
2021-04-21
Apr 21, 2021D
Completed
- Lymphoma, Follicular
- Bendamustine
- +2 more
- Scarborough, Maine
- +3 more
2021-04-27
Apr 27, 2021P
F
Terminated
- Lymphatic Diseases
- Brentuximab Vedotin
- Bendamustine
- Bologna, BO, Italy
- +4 more
2021-05-26
May 26, 2021A
Active, not recruiting
- Lymphoma, Non-Hodgkin
- +5 more
- Rituximab
- +2 more
- Providence, Rhode IslandRhode Island Hospital and The Miriam Hospital
2021-07-19
Jul 19, 2021G
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
- Cologne, GermanyGerman CLL Study Group
2021-12-13
Dec 13, 2021S
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
- Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
2021-06-03
Jun 3, 2021G
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
- Cologne, GermanyGerman CLL Study Group
2021-08-23
Aug 23, 2021U
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
- Bendamustine
- Cyclophosphamide
- Tucson, ArizonaThe University of Arizona Cancer Center
2021-05-10
May 10, 2021